Plain-English translation of NCT06256224 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing whether adding a medication called to the standard treatment for advanced cervical cancer can help more patients recover. is an immunotherapy — a drug that works by "waking up" your immune system to recognize and fight cancer cells more effectively. Half of the participants will receive along with the standard treatment (radiation, internal radiation, and chemotherapy), while the other half will receive the standard treatment alone.
Advanced cervical cancer is difficult to treat, and many patients don't recover with standard therapy alone. Cervical cancer is often driven by a virus (HPV), which can hide from the immune system. This medication is designed to help the immune system see and attack cancer cells better, potentially improving survival and recovery rates.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will undergo standard cervical cancer treatment: five to six weeks of daily radiation to your pelvis (given five days a week), along with weekly chemotherapy infusions during that time, followed by internal radiation treatments over one to two weeks. If you are in the medication group, you will also receive intravenous infusions of every three weeks for six months, and possibly up to two years if your cancer hasn't completely disappeared by the six-month check-in. You will have regular follow-up visits and imaging scans to monitor your progress.
AI-generated summary from trial data · Jul 6, 2026 · Not medical advice
China